readthroughSign in
Aug 12, 2026Weekly roundup

Novartis: TOUR006 Phase 2 results posted in CKD; eltrombopag pediatric PK study also reports out

This week brought results postings for a Phase 2 CKD trial and a pediatric aplastic anemia PK study, plus two completed real-world studies and one newly disclosed recruiting collaboration.

Five Novartis-linked records updated this week, ranging from a Phase 2 results posting to a newly visible recruiting imaging study.

  • TOUR006 (pacibekitug) in chronic kidney disease: Tourmaline Bio's Phase 2 "TRANQUILITY" trial evaluated the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 in participants with chronic kidney disease and elevated hs-CRP.1 The study enrolled 143 participants1 and results were first posted this week.
  • Eltrombopag in pediatric aplastic anemia: This Phase 2 dose-escalation study looked at eltrombopag's pharmacokinetics, given alongside immunosuppressive therapy, in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia (SAA) or recurrent aplastic anemia (AA).2 Enrollment was 51 participants2, and results were first posted this week after the study completed in January 2025.
  • Ribociclib real-world study: A completed, retrospective study looked at how ribociclib is used and tolerated in patient populations historically underrepresented in clinical trials, specifically older adults and Black/African American patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer.3 The study enrolled 945 participants3.
  • IgA nephropathy real-world study: In a completed study titled "Current Treatment Patterns and Real-World Outcomes of Patients With IgA Nephropathy in the United States," Novartis characterized real-world treatment patterns, including therapy sequences, escalation, and duration, and treatment outcomes in IgA nephropathy (IgAN) patients in the United States (US).4 The study enrolled 6286 participants4.
  • Remibrutinib brain imaging sub-study in MS: A newly posted, recruiting study sponsored by Washington University School of Medicine with Novartis as collaborator is examining people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial, using PET imaging, MRI scans, blood samples, and cerebrospinal fluid (CSF) samples collected before treatment and again six months later5 to assess remibrutinib's effect on brain and spinal cord inflammation. Planned enrollment is 15 participants5.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.